https://www.selleckchem.com/pr....oducts/e7766-diammon
The pooled incidence of severe adverse events was 0.11 (0.04-0.19). The pooled SVR12 rate after completion of the half dose regimen was as high as the full dose treatment but it was associated with less adverse events (0.06 versus 0.14). The pooled SVR12 rate was 98% (91-10 in cirrhotic patients and 100% (98-10 in non-cirrhotic patients. The endorsement of Sofosbuvir-based regimen can improve the treatment of hepatitis C virus infection in patients with advanced CKD. We aimed to assess the feasibility of SPECT and PET
Like
Comment
Share
